Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Study Details
Study Description
Brief Summary
The purpose of this observational study is to evaluate the safety and effectiveness of the Solesta Injectable Bulking Agent in the treatment of fecal incontinence through 3 years in a real world setting.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
This observational study is to evaluate the safety and effectiveness of the Solesta Injectable Bulking Agent in the treatment of fecal incontinence through 3 years in a real world setting.
Study Design
Outcome Measures
Primary Outcome Measures
- Freedom from fecal incontinence reintervention [Through 36 months after the last Solesta treatment]
The primary effectiveness endpoint is freedom from Fecal Incontinence Reintervention. Patients will be evaluated at 3, 6, 12, 24, and 36 months after the last Solesta treatment for the occurrence (or lack of occurrence) of Fecal Incontinence Reintervention. Fecal Incontinence Reintervention includes Fecal Incontinence treatment of sphincteroplasty, implantation of artificial bowel sphincter, retreatment with Solesta, graciloplasty, sacral nerve stimulation (SNS) or other surgical interventions that occur more than 3 months after the last primary Solesta treatment.
Secondary Outcome Measures
- Fecal Incontinence Quality of Life (FIQL) [Assessed at baseline, 3, 6, 12, and 36 months after last Solesta treatment.]
The effectiveness endpoint of Fecal Incontinence Quality of Life using the Rockwood instrument will be assessed at baseline, 3, 6, 12, and 36 months after last Solesta treatment. Patients will fill out a questionnaire at screening visit and at follow up visits. The Fecal Incontinence Quality of Life instrument is a questionnaire completed by patients that assesses the impact of quality of life as it relates to Lifestyle, Coping/Behavior, Depression/Self perception and Embarrassment. The FIQL instrument consists of a total of 29 questions.
- Cleveland Clinic Florida Fecal Incontinence Score (CCFIS) [Assessed at baseline,3, 6, 12, and 36 months after last Solesta treatment]
The effectiveness endpoint of CCFIS will be assessed at baseline, 6, 12, and 36 months after last Solesta treatment. The investigator will calculate the CCFIS based on a patient interview. The CCFIS is a summed score of 5 individual parameters (i.e., frequency of incontinence to gas, liquid, solid, of need to wear pad, and of lifestyle changes).
- Global Perceived Effect Score [Assessed at 6, 12 and 36 months after last Solesta treatment]
The effectiveness endpoint of Global Perceived Effect Score will be assessed at 6, 12 and 36 months after last Solesta treatment. Global perceived effect is a subjective score and reflects the patient perception of their degree of FI after treatment compared to the period before treatment and ranges from 1-7 points.
- Time to Fecal Incontinence Reintervention [Assessed from 6 to 36 months after last Solesta treatment]
For patients who undergo Fecal Incontinence Reintervention the effectiveness endpoint of Time to Fecal Incontinence Reintervention will be measured from the date of last treatment with Solesta to the date of first Fecal Incontinence Reintervention. Fecal incontinence reinterventions will include any of the following FI treatments: sphincteroplasty, implantation of artificial bowel sphincter, retreatment with Solesta, graciloplasty, SNS or other surgical interventions.
- Anatomic stability of the Solesta [Assessed at time of Solesta treatment and again at 6 and 36 months after the last Solesta treatment.]
Assess the relative anatomic stability of the Solesta Injectable Bulking Agent in a subpopulation of patients enrolled at 3-4 sites as assessed by transrectal ultrasound. Solesta will be assessed by comparing anatomical positioning of the Solesta implant, as determined by transrectal ultrasound at Visit 3a (for patients who did not receive a second Solesta treatment) or Visit 3b (for patients who received a second Solesta treatment at Visit 3a) to positioning at 6 and 36 months after the last Solesta treatment.
- Occurrence of any peri-injection device related infectious adverse events. [Assessed from time of injection up to 2 weeks after Solesta treatment]
A secondary safety endpoint will be the occurrence of peri-injection device related infectious Adverse Events for patients treated with or without prophylactic antibiotics (as decided by treating physician) prior to injection.
Eligibility Criteria
Criteria
Inclusion Criteria: A patient will be eligible for study participation if he/she meets the following criteria:
-
Able to fluently speak and understand the language in which the study is being conducted and able to provide meaningful written informed consent for the study.
-
Have FI, have failed conservative therapy (e.g., diet, fiber therapy, medications that treat diarrhea), and are scheduled to receive Solesta treatment.
-
Females must be of non-childbearing potential; or females of childbearing (reproductive) potential must agree to use an acceptable method of contraception for at least the first 6 months of study participation and have a negative urine pregnancy test at Visit 1 (Screening/Baseline) and immediately prior to receiving initial Solesta treatment. Women who are surgically sterile or those who are post menopausal for at least 2 years prior to entering the study are not considered to be of childbearing potential.
-
Willing to return to the study facility for the post treatment evaluation.
Exclusion Criteria: A patient will be excluded from the study if he/she meets any of the following criteria:
-
Is currently pregnant, breastfeeding, or is planning to become pregnant over the course of the study.
-
Has an active inflammatory bowel disease.
-
Has an immunodeficiency disorder or ongoing immunosuppressive therapy.
-
Has received previous radiation treatment to the pelvic area.
-
Has significant mucosal or full thickness rectal prolapse.
-
Has active anorectal conditions including: abscess, fissures, sepsis, bleeding, proctitis, or other infections.
-
Has anorectal atresia, tumors, stenosis or malformation.
-
Has a rectocele.
-
Has rectal varices.
-
Has presence of existing implant including Solesta, artificial bowel sphincter, or sacral nerve stimulator (activated or inactivated).
-
Has an allergy to hyaluronic acid (HA) based products.
-
Has an anastomosis to the rectum or anus within 10 cm of the dentate line.
-
Has an unstable condition (e.g., psychiatric disorder, a recent history of substance abuse) or otherwise thought to be unreliable or incapable of complying with the requirements of the post-approval study protocol.
-
Has any disorder that, in the opinion of the Investigator, might interfere with the conduct of the study.
-
Has undergone sphincteroplasty, graciloplasty, or other surgical interventions (without the use of an implanted device) for treatment of fecal incontinence within 12 months of enrollment.
-
Has any bleeding disorder.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Mayo Clinic | Scottsdale | Arizona | United States | 85259 |
| 2 | Colon and Rectal Medical Services | Los Angeles | California | United States | 90048 |
| 3 | University of California Irvine Medical Center | Orange | California | United States | 92868 |
| 4 | Galliano Private Practice | Port Charlotte | Florida | United States | 33948 |
| 5 | USF Health | Tampa | Florida | United States | 33606 |
| 6 | North Pinellas Surgical Institute | Tarpon Springs | Florida | United States | 34689 |
| 7 | Cleveland Clinic Florida Health | Weston | Florida | United States | 33331 |
| 8 | Emory University | Atlanta | Georgia | United States | 30322 |
| 9 | Georgia Regents Research Institute | Augusta | Georgia | United States | 30912 |
| 10 | The Iowa Clinic | Des Moines | Iowa | United States | 50266 |
| 11 | Colon and Rectal Surgery Associates, Ltd. | Minneapolis | Minnesota | United States | 55407 |
| 12 | Colon and Rectal Surgery, LLC | Omaha | Nebraska | United States | 68114 |
| 13 | North Shore Long Island Jewish Health Systems | Huntington | New York | United States | 11743 |
| 14 | NYU Langone Medical Center | New York | New York | United States | 10016 |
| 15 | Mount Sinai Medical Center | New York | New York | United States | 10029 |
| 16 | Cleveland Clinic Foundation Digestive Disease Institute | Cleveland | Ohio | United States | 44195 |
| 17 | University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | United States | 73104 |
| 18 | Colon and Rectal Research Foundation | Allentown | Pennsylvania | United States | 18103 |
| 19 | Drexel University College of Medicine | Philadelphia | Pennsylvania | United States | 19102 |
| 20 | University of Vermont Medical Center | Burlington | Vermont | United States | 05446 |
Sponsors and Collaborators
- Bausch Health Americas, Inc.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CL SLP001